Abstract
Phosphodiesterase-5 (PDE5) inhibitors are commonly used in the treatment of erectile dysfunction. There are a small number of case reports that associate this agent with central serous chorioretinopathy (CSCR). Our report presents the treatment approach to a 42-year-old patient who described blurred vision and metamorphopsia and was diagnosed with CSCR following the use of tadalafil, a PDE5 inhibitor.
References
Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S (2004) Central serous chorioretinopathy case-control study group. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology 111:244–249
Scheider A, Nasemann JE, Lund OE (1993) Fluorescein and indocyanine green angiographies of central serous choroidopathy by scanning laser opthalmoscopy. Am J Ophthalmol 115:50–65
Prunte C, Flammer J (1996) Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol 121:26–34
Iida T, Kishi S, Hagimura N, Shimizu K (1999) Persistent and bilateral choroidal vascular abnormalities in central serous chorioretinopathy. Retina 19:508–512
Melman A, Gingell JC (1999) The epidemiology and pathophysiology of erectile dysfunction. J Urol 161:5–11
Lue TF (1990) Impotence: a patient goal directed approach to treatment. World J Urol 8:67–74
Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA (1998) Oral sildenafil in the treatment of erectile dysfunction sildenafil study group. N Engl J Med 338:1397–1404
Lugnier C (2006) Cylic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109:366–398
Laties AM, Zrenner E (2002) Viagra (sildenafil citrate) and ophthalmology. Prog Retin Eye Res 21:485–500
Carter JE (2007) Anterior ischemic optic neuropathy and stroke with use of PDE-5 inhibitors for erectile dysfunction: cause and coincidence? J Neurol Sci 262:89–97
Foresta C, Caretta N, Zuccarello D, Poletti A, Biagioli A, Caretti L (2008) Expression of the PDE5 enzyme on human retinal tissue: new aspects of PDE5 inhibitors ocular side effects. Eye 22:144–149
Quiram P, Dumars S, Parwar B, Sarraf D (2005) Viagra-associated serous macular detachment. Graefes Arch Clin Exp Ophthalmol 243:339–344
French DD, Margo CE (2010) Central serous chorioretinopathy and phosphodiesterase-5 inhibitors: a case-control postmarketing surveillance study. Retina 30:271–274
Aliferis K, Petropoulos IK, Farpour B, Matter MA, Safran AB (2012) Should central serous chorioretinopathy be added to the list of ocular side effects of phosphodiesterase 5 inhibitors? Ophthalmologica 227:85–89
Gordon-Bennett P, Rimmer T (2012) Central serous chorioretinopathy following oral tadalafil. Eye 26:168–169
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Türkcü, F.M., Yüksel, H., Şahin, A. et al. Central serous chorioretinopathy due to tadalafil use. Int Ophthalmol 33, 177–180 (2013). https://doi.org/10.1007/s10792-012-9646-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10792-012-9646-x